ÂÜÀòÂÒÂ×

Tony has over 30 years of experience in pharmaceuticals, including an extensive tenure at Merck & Co. At Merck Frosst, Canada, Tony led teams that developed Singulair®, Cox-2 inhibitors (Vioxx® and Arcoxia®), prostaglandin DP receptor antagonist (a component of Tredaptive®), and Cat K inhibitors (odanacatib) making the Merck Frosst Laboratories the most productive discovery unit of Merck. Subsequent career highlights at Merck relating to infectious disease include the development of HIV integrase inhibitor Isentress® and the development & licensing of therapies to tackle drug-resistant bacterial infections. Tony’s most recent responsibility at Merck as head of Vaccine R&D led to the commercialization of 4 vaccines; Gardasil®, Zostavax®, Proquad®, and Rotateq®. Tony is Chairman of the Board of Directors, MSD Wellcome Trust Hilleman Labs, Board of Trustees, and President, Merck Genome Research Institute.